Estrogen plus progestin increased risk for breast cancer in postmenopausal women

November 2003
ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p61
Academic Journal
In postmenopausal women, estrogen plus progestin hormone therapy (HT) increases cases of total and invasive breast cancer and abnormal mammogram results. Women who have received HT had a greater incidence of total and invasive breast cancer than did women who received placebo. The increase in invasive breast cancer with HT was seen across almost all risk categories.


Related Articles

  • Estrogen plus progestin increased risk for breast cancer in postmenopausal women: COMMENTARY. Thacker, Holly L. // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p61 

    The study by researchers R.T. Chlebowski and colleagues gives detailed information regarding breast cancer risk in late postmenopausal women using estrogen-plus-progestin hormone therapy (HT). No increased risk for breast cancer death was reported in HT users, and the diagnosis of metastatic...

  • CANCER. PARK, ALICE // Time International (Asia Edition);2/14/2011, Vol. 177 Issue 6, p11 

    The article reports on results of a trial in Great Britain which confirms the risk of breast cancer in women who use a combination estrogen and progestin pills.

  • Journal of National Cancer Institute.  // Biomedical Market Newsletter;3/21/2012, Vol. 21, p1 

    The article presents information on a comparative study of the effect of estrogen alone and estrogen plus progestin in the case of breast cancer.

  • Putting the WHI report on breast cancer in perspective. Speroff, Leon // Contemporary OB/GYN;Aug2003, Vol. 48 Issue 8, p69 

    Presents information on a study by the Women's Health Initiative regarding estrogen-progestin therapy for the treatment of breast cancer. Results of analysis of invasive breast cancer in the treated group and in the placebo group; Implication of the mammography findings on the effects of...

  • Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women's Health Initiative Randomized Trial. McTiernan, Anne; Martin, Christopher F.; Peck, Jennifer D.; Aragaki, Aaron K.; Chlebowski, Rowan T.; Pisano, Etta D.; Wang, C. Y.; Brunner, Robert L.; Johnson, Karen C.; Manson, JoAnn E.; Lewis, Cora E.; Kotchen, Jane M.; Hulka, Barbara S. // JNCI: Journal of the National Cancer Institute;9/21/2005, Vol. 97 Issue 18, p1366 

    Background: Increased mammographic density reduces the sensitivity of screening mammography, is associated with increased breast cancer risk, and may be hormone related. We assessed the effect of estrogen-plus-progestin therapy on mammographic density. Methods: In a racially and ethnically...

  • Long-term female hormone use a risk factor for breast cancer?  // Reactions Weekly;5/20/2006, Issue 1102, p5 

    Discusses two studies which examined the effect of the long-term use of estrogen and estrogen with progestogens on the risk of breast cancer in postmenopausal women. Reference to studies published in the April 10, 2006 and May 8, 2006 issues of "Archives of Internal Medicine"; Number of breast...

  • Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women. Chlebowski, R. T.; Hendrix, S. L.; Langer, R. D. // Evidence Based Medicine;Nov2003, p172 

    The article focuses on the study concerning the relationship among estrogen plus progestin use, breast cancer characteristics, and mammography recommendations. It notes the role of oestrogen plus progestogen hormone therapy (HT) in the increase of the risk of abnormal mammographic results and...

  • Issues to debate on the Women's Health Initiative study Failure of estrogen plus progestin therapy for prevention of breast cancer risk. T. Luukkainen // Human Reproduction;Aug2003, Vol. 18 Issue 8, p1559 

    Several studies on hormone replacement therapy (HRT) in the USA have been published. They revealed that the risk of breast cancer is increased with HRT more than with estrogen alone (ERT). A progestin has been given with each dose of ERT, as was the case in the Women's Health Initiative (WHI)...

  • Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California. Ereman, Rochelle R.; Prebil, Lee Ann; Mockus, Mary; Koblick, Kathy; Orenstein, Fern; Benz, Christopher; Clarke, Christina A. // BMC Public Health;2010, Vol. 10 Issue 1, p228 

    Background: Recent declines in invasive breast cancer have been reported in the US, with many studies linking these declines to reductions in the use of combination estrogen/progestin hormone therapy (EPHT). We evaluated the changing use of postmenopausal hormone therapy, mammography screening...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics